Back
  1. Home
  2. Profile of Maxime Dubois (ULiège)
Profil

Dubois Maxime

GIGA I3 - Virology and Immunology

Département des sciences de la vie > GIGA

Virologie - Immunologie

See author's contact details
ORCID
0000-0002-1289-8415
Main Referenced Co-authors
D'arrigo, Paolo  (2)
Lebrun, Marielle  (2)
Rogister, Bernard  (2)
Sadzot, Catherine  (2)
Aldenhoff, Thérèse  (1)
Main Referenced Keywords
HSV (5); CXCL12 (4); CXCR4 (4); Glioblastome (3); migration (3);
Main Referenced Unit & Research Centers
GIGA I3-Virology and Immunology - ULiège [BE] (4)
GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège [BE] (1)
Main Referenced Disciplines
Microbiology (5)
Oncology (1)
Human health sciences: Multidisciplinary, general & others (1)
Life sciences: Multidisciplinary, general & others (1)

Publications (total 7)

The most downloaded
144 downloads
Sanchez Gil, J., Dubois, M., Neirinckx, V., LOMBARD, A., Coppieters't Wallant, N., D'arrigo, P., Isci, D., Aldenhoff, T., Brouwers, B., Lassence, C., ROGISTER, B., Lebrun, M., & Sadzot, C. (2022). Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: a proof-of-principle. Molecular Therapy: Oncolytics. doi:10.1016/j.omto.2022.06.002 https://hdl.handle.net/2268/292435

The most cited

4 citations (Scopus®)

Sanchez Gil, J., Dubois, M., Neirinckx, V., LOMBARD, A., Coppieters't Wallant, N., D'arrigo, P., Isci, D., Aldenhoff, T., Brouwers, B., Lassence, C., ROGISTER, B., Lebrun, M., & Sadzot, C. (2022). Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: a proof-of-principle. Molecular Therapy: Oncolytics. doi:10.1016/j.omto.2022.06.002 https://hdl.handle.net/2268/292435

Dubois, M. (11 November 2023). Oncolytic Herpes Simplex Virus type 1 armed with CXCL12-antagonist “P2G” to impair glioblastoma stem-like cells self-renewal and migration [Poster presentation]. 15th international oncolytic virus conference, Banff, Canada.

Dubois, M. (22 December 2022). Oncolytic Herpes Simplex Virus type 1 armed with CXCR4-antagonist “P2G” to disrupt CXCR4/CXCL12 pathway in Glioblastoma [Paper presentation]. 10th ANNUAL BELVIR MEETING, Bruxelles, Belgium.

Dubois, M. (09 September 2022). Oncolytic Herpes Simplex Virus type 1 armed with CXCL12-antagonist “P2G” to disrupt CXCR4/CXCL12 pathway in Glioblastoma [Poster presentation]. INTERUNIVERSITY PHD STUDENT DAY, Namur, Belgium.

Dubois, M. (09 September 2022). Oncolytic HSV-1 armed with P2G to disrupt CXCR4 pathway in Glioblastoma [Paper presentation]. INTERUNIVERSITY PHD STUDENT DAY, Namur, Belgium.

Sanchez Gil, J., Dubois, M., Neirinckx, V., LOMBARD, A., Coppieters't Wallant, N., D'arrigo, P., Isci, D., Aldenhoff, T., Brouwers, B., Lassence, C., ROGISTER, B., Lebrun, M., & Sadzot, C. (2022). Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: a proof-of-principle. Molecular Therapy: Oncolytics. doi:10.1016/j.omto.2022.06.002
Peer Reviewed verified by ORBi

Dubois, M. (2021). Engineering and characterization of an Oncolytic Herpes Simplex Virus type 1 armed with P2G to disrupt CXCR4 pathway in Glioblastoma Multiforme [Master’s dissertation, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/300323

D'arrigo, P., Sanchez Gil, J., Dubois, M., Lebrun, M., ROGISTER, B., & Sadzot, C. (02 August 2021). An armed oncolytic herpesvirus to counteract gioblastoma stem-like cells functions [Poster presentation]. International Herpesvirus Workshop.
Peer reviewed

Contact ORBi